Clinical Trials Logo

Filter by:
NCT ID: NCT05003414 Recruiting - Clinical trials for Rheumatoid Arthritis

The Medacta International GMK Sphere Cementless Post-Marketing Surveillance Study

Start date: January 14, 2020
Phase:
Study type: Observational

This is a Post-Marketing Surveillance study of GMK Sphere cementless knee prosthesis.

NCT ID: NCT05002569 Active, not recruiting - Melanoma Clinical Trials

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

RELATIVITY-098
Start date: October 19, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

NCT ID: NCT05002543 Recruiting - Clinical trials for Cardiac Valve Disease

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

MANTRA
Start date: June 29, 2021
Phase:
Study type: Observational [Patient Registry]

MANTRA is a prospective, multiple-arm, multi-center, global, post-market clinical follow-up study. The main objective is to monitor ongoing safety and performance of the CORCYM devices and accessories used for aortic, mitral and tricuspid valvular diseases in a real-world setting. Corcym S.r.l., is a medical device manufacturer with a broad product portfolio for cardiac surgeons, offering solutions for the treatment of aortic, mitral and tricuspid valve disease. The MANTRA Master Plan (Master Protocol) is intended as an overarching Umbrella Protocol that allows multiple sub-studies to be added, as needed. The Umbrella Master Protocol concept offers an excellent solution to provide post-marketing clinical follow-up information on the entire cardiac surgery heart valve portfolio of the sponsor in a common database, including corelab assessment of hemodynamic and structural performance, annular motion and Dynamics for one of the products. Currently, three sub-studies are planned: - MANTRA - Aortic Sub-Study - MANTRA - Mitral/Tricuspid Sub-Study (Excluding Memo 4D) - MANTRA - Memo 4D Sub-Study

NCT ID: NCT05002413 Completed - Bacteremia Sepsis Clinical Trials

Nanomotion-based Resistell AST to Determine the Antibiotic Susceptibility of Gram-negative Bacteria Causing Bacteremia and/or Sepsis

NANO-RAST
Start date: June 18, 2021
Phase:
Study type: Observational

Blood culture samples from bacteremia patients positive for Gram-negative bacteria will be tested for antibacterial susceptibility using Resistell Phenotech device. The results will be compared with current AST gold standard tests to calculate sensitivity, specificity, and accuracy of Resistell Phenotech device.

NCT ID: NCT05000099 Completed - Depression Clinical Trials

the Role of Technology in Elderly Patients

SILVER
Start date: December 2, 2020
Phase:
Study type: Observational

Starting from December 2019, the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) disease spread rapidly from China into the world, with about two Mio cases confirmed around the world. In Switzerland, more than 26'000 cases have been confirmed so far, and health authorities declared in March the needs for social isolation and have banned visits to hospitalized patients and to nursing home residents. Loneliness and isolation is a significant concern for the elderly patients as well as for their families that may significantly affect physical and mental health in both. SILVER aims to evaluate the role of programmed video calls with families: - on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-COV-2 pandemic. - in relieving the familiar caregiver anxiety and fear of death of others - in relieving the professional caregiver anxiety. SILVER is an international study involving both acute, rehabilitation geriatric units and nursing homes; we will enroll all the patients present in the participating centers. Patients will be allowed to chose between video and phone calls, the following dimensions will be evaluated: - Delirium risk: using the Confusion Assessment Method (CAM) - Mood: using the 5-item Geriatric Depression Scale (GDS) - Anxiety: using the Clinical Anxiety Scale (GAS). - Fear of death (self and others): using the Collett-Lester scale. In parallel, health professionals and family caregivers will be evaluated for anxiety at baseline and every week after intervention set-up by the Clinical Anxiety Scale (CAS). Family caregivers will also be evaluated with the fear of death scale (sub-scale fear of death of others). Finally, to evaluate the appreciation for video call communication in patients and caregivers we will use a Likert scale.

NCT ID: NCT04999566 Recruiting - Clinical trials for Metabolism, Inborn Errors

Cardiac Manifestation and Inherited Metabolic Diseases

Start date: May 1, 2021
Phase:
Study type: Observational

The aim of this study is to report and describe cardiac manifestations associated with IMD in a cohort of patients followed in a reference center for rare diseases (Lausanne University Hospital, CHUV) from 2017-2020.

NCT ID: NCT04998812 Active, not recruiting - Multiple Sclerosis Clinical Trials

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

MINORE
Start date: April 13, 2022
Phase: Phase 4
Study type: Interventional

This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

NCT ID: NCT04998370 Active, not recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Cerebrospinal Fluid Hemoglobin to Monitor for Aneurysmal Subarachnoid Hemorrhage Related Secondary Brain Injury

HeMoVal
Start date: August 18, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the association between hemoglobin levels in the cerebrospinal fluid (CSF-Hb) and the occurrence of secondary brain injury in patients after aneurysmal subarachnoid hemorrhage (SAH-SBI) during the first 14 days after bleeding.

NCT ID: NCT04997434 Completed - Pain, Acute Clinical Trials

Impact of Modern Art Therapy on Patients' Anxiety and Pain During the Waiting Time in an Emergency Department

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to investigate whether, during a waiting period in an emergency department, the patient's participation in a modern art therapy session decreases the patient's level of anxiety and pain. As a secondary objective, this study aims to explore whether participation in a modern art therapy session is perceived positively by the patient. This objective will be assessed by both patient self-report and art therapist heteroreport. In this work, the investigators will therefore seek to demonstrate the potential positive impact of modern art therapy conducted during times of waiting for examination or results.

NCT ID: NCT04997317 Recruiting - Meningioma Clinical Trials

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

PROMENADE
Start date: April 21, 2021
Phase: Early Phase 1
Study type: Interventional

Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently used in advanced, recurrent or progressive meningiomas with promising results. In this study, the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter will be assessed.